Business
Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Operational Highlights
Announced partnership with Australian CRO to accelerate initiation of CLD-401 clinical trialThe Company has received feedback from the FDA through Type D interactions, and the Company believes its manufacturing and analytical approaches for CLD-401 are in alignment with FDA guidance; Calidi expects to file an IND by end of 2026Partnered with Matica Bio around the GMP manufacturing of CLD-401Presented new data on in situ T-cell engagers (TCEs) at 2026 AACR-IO conferenceRaised $6.5 million in publ
About this update from Calidi Biotherapeutics, Inc.
[{"type":"image","alt":"Calidi Biotherapeutics, Inc","displaySize":"","headline":null,"caption":"Calidi Biotherapeutics, Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":93,"url":"https://media.zenfs.com/en/globenewswire.com/8983e19176ab43568fb63e4ece5ad7a1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/wX9t4eJfVQL9R1_CtWiapg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzMA--/https://media.zenfs.com/en/globenewswire.com/8983e19176ab43568fb63e4ece5ad7a1","width":300,"height":93}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Announced partnership with Australian CRO to accelerate initiation of CLD-401 clinical trial","length":92,"tagName":"p"}]},{"val":[{"type":"text","content":"The Company has received feedback from the FDA through Type D interactions, and the Company believes its manufacturing and analytical approaches for CLD-401 are in alignment with FDA guidance; Calidi expects to file an IND by end of 2026","length":237,"tagName":"p"}]},{"val":[{"type":"text","content":"Partnered with Matica Bio around the GMP manufacturing of CLD-401","length":65,"tagName":"p"}]},{"val":[{"type":"text","content":"Presented new data on in situ T-cell engagers (TCEs) at 2026 AACR-IO conference","length":79,"tagName":"p"}]},{"val":[{"type":"text","content":"Raised $6.5 million in public offering and ATM sales","length":52,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":525,"olType":false},{"type":"text","content":"SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today reported its fourth quarter and full-year 2025 operating and financial results and reviewed recent business highlights.","length":332,"tagName":"p"},{"type":"text","content":"“We are extremely excited about the continued progress at Calidi,” said Eric Poma, PhD, CEO of Calidi Biotherapeutics. “We continue to advance CLD-401, the first lead from our RedTail platform, towards the clinic and have built a world-class scientific advisory board to aid those efforts. We have also expanded what the RedTail platform can do with our new approach of in situ T-cell engagers.”","length":395,"tagName":"p"},{"type":"text","content":"Fourth Quarter 2025 and Recent Corporate Developments",...